Business Unit New Technology
The "New Technology" business unit comprises the core technologies of AVA LifeScience to identify and develop our products.
The business unit homes our proprietary technology platform for the selection of NextGenMonoclonal® antibodies with unique target specifity and the ability to discriminate single amino acid changes in target proteins.
We also develop the tools and strategies for effective companion diagnostics.
Our current focus is on B cell malignancies.
Our current focus is on B cell malignancies where we generate tumor-specific antibodies targeting aggressive subgroups of chronic lymphatic leukemia (CLL).
In addition, we are in the planning phase to address other B cell malignancies such as mantle cell lymphoma and follicular lymphoma.
Our future perspective is on the development of specific antibodies for autoimmune diseases such as multiple sclerosis or rheumatoid arthritis.